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DNA-binding anticancer agents cause alteration in
chromatin structure and dynamics. We report the
dynamic interaction of the DNA intercalator and
potential anticancer plant alkaloid, sanguinarine
(SGR), with chromatin. Association of SGR with
different levels of chromatin structure was enthalpy
driven with micromolar dissociation constant. Apart
from DNA, it binds with comparable affinity with
core histones and induces chromatin aggregation.
The dual binding property of SGR leads to inhibition
of core histone modifications. Although it potently
inhibits H3K9 methylation by G9a in vitro, H3K4 and
H3R17 methylation are more profoundly inhibited in
cells. SGR inhibits histone acetylation both in vitro
and in vivo. It does not affect the in vitro transcription
fromDNA template but significantly represses acety-
lation-dependent chromatin transcription. SGR-
mediated repression of epigenetic marks and the
alteration of chromatin geography (nucleography)
also result in the modulation of global gene expres-
sion. These data, conclusively, show an anticancer
DNAbinding intercalator as amodulator of chromatin
modifications and transcription in the chromatin
context.
INTRODUCTION
Sanguinarine (13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo [4,
5-i] phenanthridium), a plant alkaloid, is derived from the root of
Sanguinaria canadensis, Argemone mexicana, and other poppy-
fumaria species (Shamma and Guinaudeau, 1986). It possesses
antimicrobial, antioxidant, anti-inflammatory, and proapoptotic
properties (Malikova et al., 2006; Adhami et al., 2003; Mandel,
1994). It is a potent inhibitor of nuclear factor kB (NF-kB) activa-
tion and consequent cell growth and survival (Chaturvedi et al.,
1997). SGR blocks proliferation and induces apoptosis in
different malignant cell types (Hussain et al., 2007; AdhamiChemistry & Biology 16, 203et al., 2003). It induces cell cycle arrest at the G0/G1 phase
(Adhami et al., 2004). These effects originate from the ability
of SGR to target a variety of cellular components (Wolff and
Knipling, 1993; Vogt et al., 2005; Barreto et al., 2003; Wang
et al., 1997; Straub and Carver, 1975; Vallejos, 1973; Ulrichova
et al., 2001).
The cationic form of the drug at pH 6.5 binds reversibly to
B DNA with GC base preference via intercalation (Maiti et al.,
2002; Das et al., 2003; Maiti and Kumar, 2007). Although in
recent years extensive investigation is being done to understand
the basis of potential antineoplastic activity of SGR, the molec-
ular target(s) is yet to be identified. Its potent antiproliferative
and DNA intercalation property prompted us to investigate the
interaction of the drug with chromatin and the structure-function
consequences thereof.
As a first step, we have estimated the binding parameters and
associated energetics of the association at different levels of
chromatin structure by means of fluorescence, circular
dichroism (CD) spectroscopy, and isothermal titration calorim-
etry (ITC). The trend in the change of enthalpy with the tempera-
ture (heat capacity changes) for binding has given information
about the structural alterations of the chromatin, mononucleo-
some, and chromosomal DNA consequent to the association.
CD spectroscopy was used as the preliminary probe for SGR-
induced structural alterations. We have probed the SGR induced
alteration in the size distribution of chromatin and mononucleo-
some by means of dynamic light scattering. Moreover, confocal
and atomic force microscopy have been used for direct visuali-
zation of the ligand-induced alteration of the in vivo chromatin
organization. We have also noticed that in addition to DNA,
SGR binds to the core histoneswith comparable affinity. Further-
more, we have addressed the effect of chromatin structure
perturbation and the histone binding potential of SGR on the
dynamicity of chromatin that modulates the different DNA-tem-
plated phenomena in the cell. There are several factors that
contribute to the chromatin dynamics, including posttransla-
tional modifications of chromatin associated proteins (histones
and nonhistones) and ATP-dependent chromatin remodeling
machinery (Kouzarides, 2007; Hogan and Varga-Weisz, 2007).
Among the different posttranslational modifications, reversible
acetylation, phosphorylation, and methylation are directly in-
volved in the regulation of gene expression (Kouzarides, 2007).–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 203
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Sanguinarine Alters Chromatin ModificationsDysfunction of chromatin modification is causally related to the
cancer manifestation (Jones and Baylin, 2007). For example, hy-
peracetylation of histones (Van Beekum and Kalkhoven, 2007),
mistargeting/misregulation of histone deacetylases (Nakagawa
et al., 2007) and acetyltransferases (Rothhammer and Bosserh-
off, 2007), overexpression of histone kinases (Oki et al., 2007),
and alteration of the histone methyltransferases and tumor
suppressor interactions (Tonini et al., 2008) are commonly docu-
mented in different cancer manifestation. Thus, these chromatin
modifying enzymes are being considered as new-generation
therapeutic targets for cancer therapy (Swaminathan et al.,
2007).
Remarkably, we have found that SGR inhibits histone methyl-
ationwith an inherent specificity toward lysine and argininemeth-
ylation linked to transcriptional activation. It is a potent inhibitor of
histone acetylation (HATs) in vitro and in vivo, as observed in cell
lines and mouse liver. Although SGR intercalates into DNA base
pairs, when it binds to DNA devoid of histones it does not appar-
ently inhibit the transcription from DNA template. In contrast, it
inhibits the p300-HAT-dependent chromatin transcription.
However, the physiologically relevant concentration for the inhi-
bition of histone acetylation does not induce proapoptotic gene
expression, thereby indicating that the interaction of SGR with
different chromatin components leading to inhibition of histone
modifications is independent of its well-documented role in
apoptotic pathway. This was further verified by examining the
global gene expression profile of cells treated with both low
and high concentrations of SGR. We observe a differential
pattern of gene regulation based on the dosage. The treatment
with a low concentration for a shorter duration results in about
55% downregulation of genes. However, when the dosage is
increased, upregulation of gene expression is much more
profound. The results, in totality, might provide a new direction
for the molecular mechanisms of action of DNA intercalators
with anticancer properties, particularly those with dual binding
ability toDNAandcore histones. It also suggests thepossible tar-
geting of multiple enzymes by a single molecular species, espe-
cially in the area of antineoplastic therapeutics.
RESULTS
Characterization of SGR Association with Chromatin
Sanguinarine is an established intercalator class of DNA-binding
alkaloid (Figure 1A), with high cell permeability potential.
Although substantial work has been done regarding the effect
of SGR on different cell lines and in an animal model (Adhami
et al., 2004; Dvorak and Simanek, 2007), surprisingly no report
is available about its interaction with chromatin and its constit-
uent components such as histones. Association of SGR with
chromatin, mononucleosome, and chromosomal DNA (subse-
quently denoted as polymers) was probed by fluorescence
spectroscopy. Blue shift of emission maximum of SGR with
a concomitant decrease in quantum yield in the fluorescence
spectrum is the preliminary evidence for the binding of SGR
with different levels of chromatin structure (polymers) (see
Figure S1 available online). Both are dependent on the nature
of the polymer. The binding isotherms generated from fluores-
cence measurements suggest noncooperative association
(Figure 1B). Corresponding dissociation constants evaluated204 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsfrom nonlinear curve fitting of binding isotherms are summarized
in Table 1. The value of the binding stoichiometry and dissocia-
tion constant for association of SGR with HeLa chromatin are 6
bases per SGR and 8 mM, respectively, which is in good agree-
ment with the similar values for rat liver chromatin (Table 1). The
dissociation constant value for chromosomal DNA is of the same
order as reported earlier for calf thymus DNA and synthetic
polynucleotide (Das et al., 2003), thereby supporting the results
obtained from the fluorescence method.
The local electronic environment of SGR during its interaction
with different chromatin components was probed by means of
excited state lifetime measurements of the SGR fluorophore.
Fluorescence decays could be fitted with a biexponential func-
tion. Mean lifetime decreases in the order: chromosomal DNA
(10.6 ns) > chromatin (8.8 ns) > mononucleosome (6.3 ns). The
decay profile of free SGR in Tris-HCl buffer (pH 6.5) could be
fitted well with a biexponential function with t1 = 2.5 ns and
t2 = 0.15 ns. Increase in lifetime upon interaction with polymers
could be attributed to an increase in hydrophobicity of themicro-
environment originating from intercalation of SGR within DNA
base pairs (Prendergast, 1991). However, dependence of the
lifetime upon association of DNA with histones in chromatin
and mononucleosome implies a difference in their local environ-
ment of SGR fluorophore. In case of chromatin andmononucleo-
some, the physical environment from associated proteins,
especially histones, could be the other plausible source of
enhanced lifetime. To test our hypothesis, we investigated the
possibility of interaction of SGR with core histones by fluores-
cence spectroscopy. Quenching of SGR fluorescence accom-
panied by blue shift provides the direct physical evidence for
the association of histoneswith SGR (Figure 2B). Nonlinear curve
fitting analysis of the noncooperative binding isotherm yields the
dissociation constant (Kd) value of 8.8 mM.
Isothermal calorimetric titrations were performed to evaluate
the binding parameters and associated energetics of SGR-poly-
mer binding. A representative titration thermogram and binding
isotherm for SGR-chromatin association are shown in Figure 1C.
Dissociation constants and binding stoichiometry values
obtained from ITC measurements compare well with those esti-
mated from fluorescence titration (Table 1). Association is
enthalpy driven in all cases. Variation of enthalpy and entropy
with temperature decreases in order: mononucleosome >
chromatin > chromosomal DNA (Figures 1D and 1E). Taken
together, these results suggest that SGR not only binds to
DNA, but it also interacts with core histone component of chro-
matin with comparable affinity.
Sanguinarine Induces Conformational Changes
by Interacting with Chromatin
The effect of SGR on the structure of native chromatin, mononu-
cleosome, and chromosomal DNA was examined by CD spec-
troscopy. Spectra for native chromatin, mononucleosome, and
chromosomal DNA agree well with previous reports (Murcia
et al., 1978; Vergani et al., 1994). Optically inactive SGR (400 nm
to 220 nm) exhibits positive induced band upon intercalation
within DNA base pairs (Das et al., 2003). Emergence of induced
CD band (310–380 nm) thus demonstrates SGR-polymer associ-
ation.Relevant spectra are shown inFigure 2A (panels I, II, and III).
Because the induced band originates from optically asymmetricevier Ltd All rights reserved
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Sanguinarine Alters Chromatin Modificationsenvironment from DNA and DNA-protein complexes, difference
in their peak positions (Figure 2A) suggests nonidentical optical
environments of SGR bound to different levels of chromatin.
Marked alterations in the spectra of chromatin andmononucleo-
some (300 nm to 230 nm) also characterize their association with
SGR. Inset I of Figure 2A shows the time-dependent decrease in
the ellipticity at 272 nm, an index of chromatin aggregation. CD
spectroscopic results were supported from the thermodynamic
data. Magnitude of DCp (calculated from the slope of linear fit
of the plot DH versus T) is an index of the ligand-induced alter-
ation of the polymer structure, particularly the solvent exposed
surface area. Large positive DCp in case of mononucleosome
suggests that SGR induces its structural alteration to a signifi-
cant degree (Figure 1D and Table 1). Similarly, DCp for SGR-
chromatin binding implies an SGR-induced radical change in
chromatin structure upon association with SGR. Dynamic light
scattering measurements were done to further characterize
the ultrastructural consequences of SGR association with chro-
matin, mononucleosome, and chromosomal DNA (Figure 2C, I
and II). There was a clear increase in the mean hydrodynamic
Figure 1. SGR Interacts with Histones
(A) Structure of SGR.
(B) Curve-fitting analyses to evaluate the dissocia-
tion constant for the association of SGR with
different levels of chromatin structure: chromatin
(B), mononucleosome (D), and chromosomal
DNA (,) in 10 mM Tris-HCl (pH 6.5) at 25C.
Dissociation constant values obtained from the
fitting of the binding isotherms by the nonlinear
least-squares method are 10 mM, 12 mM, and
17 mM for chromosomal DNA, chromatin, and
mononucleosome, respectively. The concentra-
tion of SGR taken was 5 mM in all three cases.
(C) Exchange of heat of association of SGR with
chromatin. Upper panel is the isothermal calori-
metric titration of 1.2 mM chromatin into 10 mM
SGR at 25C in 10 mM Tris-HCl buffer (pH 6.5).
Lower panel is the exothermic heat exchanged
per mole of injectant as a function of molar ratio
of chromatin to SGR. The data were fitted with
the ‘‘one set of sites’’ binding model. Solid line
represents the fit of the binding isotherm.
(D) Temperature dependence of calorimetric
enthalpy of association between SGR and chro-
matin (B), mononucleosome (D), and chromo-
somal DNA (,). The lines represent the fits of
data to equation DH (T) = DH (T0) + DCp*(T-T0).
Values of DCp obtained from the fits are 0.2,
0.09, and + 0.40 kcal mol1 K1 for chromatin,
chromosomal DNA, and mononucleosome,
respectively.
(E) Temperature dependence of calorimetric
entropy of association of SGR with different levels
of chromatin structures: chromatin (B), mononu-
cleosome (D), and chromosomal DNA (,).
diameter of chromatin in presence of
SGR, suggesting that the alkaloid induces
chromatin aggregation in vitro. However,
SGR itself does not get aggregated in
solution, as tested by ITC at different
pH conditions (Figure S2). In contrast, there is no significant shift
in the mean hydrodynamic diameter of mononucleosome and
chromosomal DNA in presence of bound SGR. SGR-induced
increase in hydrodynamic diameter implying aggregation of
chromatin was also checked in vivo on HeLa cells by confocal
(Figure 2D) and atomic force microscopy (Figure 2E). Unlike
the untreated or dimethyl sulfoxide (DMSO, solvent) treated
cells, SGR treatment leads to the aggregation of chromatin
into distinct large foci (Figure 2D, I and II; Figure 2E, I; compare
panels i and ii with iii). For the finer understanding of the alter-
ation of nuclear architecture upon SGR treatment, the isolated
HeLa nuclei were subjected to atomic force microscopy (AFM)
analysis upon partial micrococcal nuclease digestion (Figure 2E,
panel II). The untreated or DMSO-treated nuclei were found to
be uniformly digested by MNase, but SGR-treated nuclei that
were highly aggregated were accessible to a variable extent
due to the formation of large compact chromatin domains (Fig-
ure 2E, panel II; compare iv and v with vi). These results suggest
that interaction of SGR induces chromatin aggregation in the
cells.Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 205
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Sanguinarine Alters Chromatin ModificationsTable 1. Thermodynamic Parameters and Stoichiometry of Binding for the Association of SGRwith Chromatin, Mononucleosome, and
Chromosomal DNA in 10 mM Tris-HCl (pH 6.5) at 25C
Kd
a (mM) n (Bases/Drug) DH (kcal/Drug) DS (e.u.e) DCP (kcal$mol
1$K1)
Chromatin 3.3 ± 0.3b 6 ± 0.5b 9.8 ± 0.3b 7.1 ± 0.1b 0.2b
12 ± 0.5c 6 ± 0.5c
8 ± 0.5d 6 ± 0.5d
Mononucleosome 10 ± 0.5b 8 ± 0.5b 7.4 ± 0.4b 2.5 ± 0.2b +0.4b
17 ± 0.5c 8 ± 0.5c
Chromosomal DNA 1.1 ± 0.3b 4 ± 0.1b 8 ± 0.3b 4 ± 0.1b 0.09b
10 ± 0.3c 4 ± 0.1c
a Kd is the apparent dissociation constant (Kd = K0 3 n, where K0 is the intrinsic dissociation constant and n is the binding stoichiometry).
b Values were determined by the calorimetric method.
c Values were determined by the fluorimetric method.
d Represents the values for HeLa chromatin.
e Entropy units.Sanguinarine Inhibits Histone Methylation
with Differential In Vivo Dynamics
Previous experiments clearly suggest that SGR interacts with
chromatin both through histones and DNA. Its ability to interact
with the histones encouraged us to find out whether SGR alters
the state of chromatin modifications. The relatively stable
histonemodification, methylation of lysine, and arginine residues
play an important role in the different cellular functions alongwith
other chromatinmodifications. Histonemethylation can be asso-
ciated with both gene activation and repression based on the
residue and modification status. It was observed that SGR could
inhibit the lysine methyltransferase G9a-mediated histone meth-
ylation with an IC50 of approximately 5 mM as revealed by a filter
binding assay (Figure 3A, compare lane 3 with lanes 4–7). The
filter binding assay was further confirmed by fluorographic gel
assay, which showed that the methylation of histone H3 by
G9a was efficiently inhibited by SGR (Figure 3B). Methylation
of arginine residues by PRMT4/CARM1 was also found to be
inhibited by SGR, with an IC50 value of 10 mM both by filter
binding and fluorographic gel assay (Figure 3A, compare lane
3 with lanes 4–7; Figure 3C). Inhibition of histone methylation
in vivo by SGR was found to be quite interesting (see Discus-
sion). Methylation of histone H3, at K9 was least affected in pres-
ence of 2 mMconcentration of SGR in HeLa cells, as observed by
western blot analysis (Figure 3D, panel I), whereas the methyla-
tion marks associated with transcriptional activation, asym-
metric dimethylation of histone H3R17, and trimethylation of
H3K4were drastically inhibited by SGR at a similar concentration
(2 mM) (Figure 3D, panels II and III, respectively). These results
indicate that binding of SGR to chromatin inhibits H3K4 and
H3R17 methylation, an epigenetic mark associated with tran-
scriptional activation, more efficiently than H3K9 methylation,
a marker for silent heterochromatin.
Sanguinarine Is a Potent Inhibitor of Histone Acetylation
Methylation of histone H3K4 and H3R17 along with the acetyla-
tion of specific sites (both in H3 and H4) marks the transcription-
ally active state of a gene. Therefore, we investigated whether
SGR could also modulate histone acetyltransferase activity.
Interestingly, in vitro histone acetyltransferase assays using
two different classes of histone acetyltransferases, p300 and
PCAF, clearly showed that SGR could efficiently inhibit histone206 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsacetyltransferase activity with an approximate IC50 value of
10 mM (Figure 4A). Quantitative filter binding assay was further
confirmed by gel fluorography assay. The results showed that
5–20 mM SGR gradually inhibited the acetylation of histones H3
and H4 very potently (Figures 4B and 4C, lanes 5–7). Because
SGR is highly permeable to cells, the inhibition of histone acety-
lation was confirmed by western blot analysis of extracted
histones from the SGR-treated cells. In agreement with the
in vitro HAT assays, it was found that in presence of SGR, acet-
ylation of histone H3 was significantly inhibited even at 2 mM
concentration when treated for only 3 hr (Figure 4D compare
lane 2 with lanes 3 and 4). We further investigated the transient
changes in the state of histone acetylation in mice liver upon
SGR treatment. Interestingly, there was a drastic reduction of
histone acetylation in the liver of mice injected with SGR
(25 mg/kg body weight) as compared with the solvent (DMSO)
control, observed within 6 hr (Figure 4E, panel II; compare
DMSO with SGR). However, the drug treatment did not induce
any apparent toxicity to the animal because the morphology of
the cells did not show any significant change. Taken together,
these data establish SGR as a potent inhibitor of histone acety-
lation in vitro and in vivo.
Sanguinarine Does Not Affect the DNA Transcription
but Inhibits the Acetylation-Dependent Chromatin
Transcription
Sanguinarine strongly binds to DNA via intercalation and also
interacts with histones, resulting in the inhibition of different
chromatin modifications associated with transcriptional activa-
tion. Therefore, we were interested to find out the effect of
SGR on the first level of gene expression, transcription. For
this purpose, the in vitro transcription experiments were per-
formed following the schemedepicted in Figure 5A. Interestingly,
the presence of a 10–25 mM concentration of SGR did not have
a significant effect on transcription from the naked DNA template
(Figure 5B, compare lane 3 with lanes 4–6). However, acetyla-
tion-dependent transcription from an in vitro assembled chro-
matin template showed a dose-dependent inhibition in the
presence of SGR (Figure 5E compare lane 3 with lanes 4–6).
Further increase in the SGR concentration up to 75 mM did not
affect the DNA transcription, though the transcription from the
chromatin template was almost completely inhibited at similarevier Ltd All rights reserved
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Sanguinarine Alters Chromatin ModificationsFigure 2. SGR Induces Conformational Changes upon Interacting with Chromatin
(A) Circular dichroism spectra of 10 mMSGR alone (.) and in presence of 39 mMpolymer (—) in 10mM Tris-HCl (pH 6.5) at 25C. Panels I, II, and III correspond to
chromatin, mononucleosome, and chromosomal DNA, respectively. Spectrum 2 (- - -) is the only polymer (39 mM) in all three cases. Inset of (A) is the plot of molar
ellipticity value at 272 nm (q272) versus time for chromatin.
(B) Panel I: Fluorescence quenching of SGR in presence of histone octamer for SGR alone (5 mM, spectrum 1) and in the presence of octamer (5 mM, spectrum 2;
8 mM, spectrum 3; 16 mM, spectrum 4). Panel II: Best fit curve of the binding isotherm generated by nonlinear least-squaresmethod for the association of SGRwith
octamer under previously mentioned conditions.
(C) Intensity distribution (%) of different levels of chromatin structure as a function of size (in diameter) obtained from DLSmeasurements. Figures in the left panel
represent chromatin, mononucleosome, and chromosomal DNA (from top to bottom), respectively. Figures in the right panel represent corresponding polymer
complexed with SGR. All experiments were done in 10 mM Tris-HCl (pH 6.5) at 25C.
(D and E) Global chromatin organization upon treatment with SGRwas probed by confocal (D) and atomic forcemicroscopy (E). Panel DI and DII (i, ii, iii) and panel
EI (i, ii, iii) are images of intact nuclei. Panel EII (iv, v, vi) are AFM images uponMNase digestion. (i), (ii), and (iii) in (D, E) represent the untreated, DMSO-treated, and
5 mM SGR-treated cells. (iv), (v), and (vi) in (E) are MNase-digested images after similar treatments.concentration (Figures 5C and 5D, compare lane 3 versus with
4–6). The inhibition of HAT-dependent in vitro chromatin
transcription clearly indicates that SGR interacts with the physi-
ological substrate chromatin and thereby blocks the histone
acetylation, which is a prerequisite step for any transcription to
occur from such a chromatin template.Chemistry & Biology 16, 203Sanguinarine Treatment Modulates Global Gene
Expression Differentially with Different Dosage
Sanguinarine inhibits histone-acetylation-dependent transcrip-
tion and leads to the repression of the epigenetic modifications
related to active transcription foci in vivo. These observations
prompted us to investigate the effect of SGR in global gene–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 207
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Sanguinarine Alters Chromatin ModificationsFigure 3. SGR Inhibits Histone Methylation
(A–C) HMTase assayswere performed in the presence or absence of SGR using highly purifiedHeLa core histones (800 ng) and processed for filter binding (A) and
gel assay fluorography (B, C). Lane 1, without any HMTase; lane 2, with HMTase; lane 3, with HMTase and in the presence of DMSO as solvent control; lanes 4–7,
with HMTase and in the presence of 5, 10, 15, and 20 mM concentrations of SGR, respectively.
(D) Histones extracted from the compound-treated cells and subjected to western blotting analysis with antibodies against methylated H3K9 (I), H3R17 (II), and
H3K4 (III) antibodies. Lane 1, untreated cells; lane 2, DMSO (solvent control) treated cells; lanes 3 and 4, 1 and 2 mM SGR-treated cells. Loading and transfer of
equal amounts were confirmed by immunodetection of histone H3 (IV).regulation. However, it is known that SGR induces apoptosis.
Therefore, to investigate the probable effect of SGR mediated
alteration of epigenetic marks and the subsequent global gene
regulation, HeLa cells were treated with a 2 mM concentration208 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elseof SGR for 3 hr. At this time point, the inhibition of histone acety-
lation becomes evident but apoptosis is not induced (Figure S3).
Microarray hybridization of the treated samples revealed the
expression of about 378 genes downregulated and 348 genesvier Ltd All rights reserved
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Sanguinarine Alters Chromatin ModificationsFigure 4. SGR Is a Potent Inhibitor of HATs
(A–C) Histone acetyltransferase assays were performed in the presence or absence of SGR using highly purified HeLa core histones (800 ng) and processed for
filter binding (A) and gel assay fluorography (B, C). Lane 1, without any HAT; lane 2, with HAT; lane 3, with HAT and in the presence of DMSO as solvent control;
lane 4, with HAT in the presence of garcinol (100 mM); lanes 5–7, with HAT and in the presence of 5, 10, 15, and 20 mM SGR respectively.
(D) Histones extracted from the compound treated cells and subjected to western blotting analysis with antibodies against acetylated histone H3. Lane 1,
untreated cells; lane 2, DMSO (solvent control) treated cells; lanes 3 and 4, 1 and 2 mMSGR-treated cells. Loading and transfer of equal amounts were confirmed
by immunodetection of histone H3.
(E) Upon treatment, mice liver tissue was processed for IHC analysis. Haematoxylin and eosin staining (I) and immunohistologic staining using acetylated histone
H3 antibody (II) were performed.Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 209
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Sanguinarine Alters Chromatin ModificationsFigure 5. SGR Does Not Affect Transcription from DNA Template but Inhibits p300 Histone Acetyltransferase-Dependent Chromatin
Transcription
(A–E) A schematic representation of in vitro transcription protocol. In vitro transcription from naked DNA template (B and D) and chromatin template (C and E).
Freshly assembled chromatin template or equivalent amount of DNA (28 ng) was subjected to the protocol described in (A) with or without SGR. Lane 1, without
activator (basal transcription); lane 2, with activator (Gal4-VP16); lane 3, with activator and DMSO; lanes 4–6, with activator and different concentration of SGR (as
indicated).upregulated (Figure 6A and Table S1). Among the upregulated
genes, there was significant modulation of genes involved in
cell signaling, focal adhesion, extracellular matrix (ECM) receptor
interaction, and complement coagulation cascades. The genes
that were downregulated were mostly frommetabolic pathways,210 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsindicating an early event of metabolic downregulation on SGR
treatment. Few representative genes were selected for the vali-
dation as represented in Figure 6B. Out of these, CHFR3
(complementH related factor 3), a component of thecomplement
system, was found to be significantly upregulated. One of theevier Ltd All rights reserved
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Sanguinarine Alters Chromatin ModificationsFigure 6. SGR Modulates Global Gene Expression
(A) Microarray analysis of gene expression upon treatment of HeLa cells with SGR. Lane 1 represents the forward reaction and lane 2 represents the dye swap.
(B) Validation of differentially altered genes by using real-time polymerase chain reaction (RT-PCR). CHFR3 and PRKCH represent upregulated genes. MEF2C
and DPPA2 represent downregulated genes.
(C) Microarray analysis of gene expression upon treatment of HeLa cells with SGR. Lanes 1, 2, and 3 represent forward reaction, and lanes 4 and 5 represent dye
swap.
(D) Validation of differentially altered genes by using RT-PCR. PLIN and DIABLO represent upregulated genes. ATF6 and HMGA2 represent downregulated
genes.components of the protein signaling cascade, PRKCH (protein
kinase C), was also upregulated upon SGR treatment. However,
an almost equivalent number of genes were also downregulated.
MEF2C (myocyte enhancer factor 2),which itself is a transcription
factor, was found to be downregulated. Another candidate gene,
DPPA2 (differentiation associated pluripotency protein), also
showed downregulated expression with SGR treatment. The
role of epigenetic modifications in SGR-mediated induction of
apoptosis was further investigated by using a higher dosage of
SGR (5 mM for 12 hr) and was followed by microarray analysis.
However, the induction of apoptosis was confirmed by the
expression of Bax (Figure S3). A total of 225 genes were
upregulated and a veryminor proportion of 35 geneswere down-
regulated (Figure 6C) as a result of this treatment. The apoptosis-
related genes were essentially upregulated (Table S2). The vali-
dation of the genes was done with few representative genes.
(Figure 6D). PLIN (perilipin), a gene involved in lipid metabolism,
was upregulated. Another important gene, DIABLO (direct IAP-
binding protein with low pI), which is required for caspase activa-
tion for proper induction of apoptosis, was also significantly
upregulated. Among the downregulated genes, ATF6 (activating
transcription factor), an ER-induced stress protein that gets
attenuated during apoptosis, was downregulated. One of the
nonhistone proteins involved with maintaining the structural
architecture of chromatin, HMGA2 (high mobility group protein
A2), was also significantly downregulated, indicating the effect
of SGR treatment on the structural integrity of chromatin as
well. Taken together, these results suggest that apart from its
role as an inducer of apoptosis and a DNA-damaging agent,
SGR might also alter cellular homeostasis by modulating epige-
netic marks through its direct interaction with chromatin.
DISCUSSION
In the present study, we have investigated both structural and
functional consequences of interaction of the well-known puta-Chemistry & Biology 16, 203tive anticancer therapeutic, SGR, with chromatin. Biophysical
studies show that SGR, a well-known DNA-intercalating agent,
can also bind to core histones. This dual-binding ability has
been hitherto unreported for a DNA-binding putative anticancer
agent. It induces radical structural alterations at both the mono-
nucleosomal and chromatin level. Alteration at the mononucleo-
somal level is confined to an increase in its solvent-exposed
surface area as a sequel to the unfolding of its structure. Such
unfolding might be triggered by the dual-binding ability of SGR.
However, SGR induces chromatin aggregation as indicated
from circular dichroism, ITC, and dynamic light scattering
measurements. The functional consequence of the dual-binding
ability of SGR is manifested in its ability to inhibit the activity of
histone acetyltransferases and histone methyltransferases,
presumably through its direct interaction with core histones.
Although SGR intercalates into DNA base pairs, it does not affect
activator-dependent in vitro transcription from DNA template.
However, emphasizing the functional importance of its inhibition
of histone-modifying enzymes, it could inhibit acetylation-depen-
dent chromatin transcription. In agreement with this phenom-
enon of involvement of the epigenetic mechanism, the global
gene expression analysis with two different concentration of
SGR treatment indicates a differential pattern. The preapoptotic
stage indicates analmost equal upregulation anddownregulation
of gene expression due to the repression of epigeneticmarks and
the alteration of chromatin structure due to SGR interaction.
Observed blue shift of fluorescence peak in the steady-state
fluorescence spectra could be due to either or both of the
following processes: ground and/or excited-state stabilization
of SGR and reduced dissipation of energy due to solvent interac-
tion in the excited state of SGR upon intercalation. Extent of blue
shift follows the order: chromatin > mononucleosome > chromo-
somal DNA (data not shown). This might be ascribed to the fact
that solvent accessibility of SGR is least when it is bound to chro-
matin. As a result, energy dissipation due to solvent interaction in
the excited state is also least for chromatin. On the other hand,–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 211
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with chromosomal DNA. However, the possibility of additional
interaction with histones in stabilizing the ground state of SGR
cannot be excluded. The analysis of excited-state fluorescence
lifetimes of bound SGR provides an explanation. If energy dissi-
pation due to solvent interaction of bound SGR for chromosomal
DNA is the sole factor for the observed minimum blue shift of
fluorescence maxima, then a lower excited-state lifetime for
chromosomal DNA as compared with chromatin and mononu-
cleosome could be expected. Interaction with chromosomal
DNA exhibits maximum lifetime among the polymers. The
apparent anomaly can be ascribed to the potential of the DNA
intercalator to interact with histones within chromatin andmono-
nucleosome. Results from fluorescence assays of SGR-core
histone association (Figure 2B) reinforce the above fact.
Different stoichiometry valuesof SGR for the chromatin,mono-
nucleosome and chromosomal DNA (Table 1) are similar to other
DNA-binding drugs like chromomycin, mithramycin, and dauno-
mycin (Mir and Dasgupta, 2001, and references therein). Nega-
tive DCp values (Table 1) are proportional to the reduction in
water-accessible nonpolar surface area of the ligand (Ortiz-Sal-
meron et al., 1998). The negative DCp value of 90 cal.mol
1.K1
for chromosomal DNA originates from the removal of water-
accessible nonpolar ring structures of SGR from bulk solution
to inside base pairs, when it intercalates into DNA base pairs.
Higher magnitude of negative DCp for chromatin relative to chro-
mosomal DNA originates from aggregation of chromatin. The
largest value of DCp with opposite sign in case of mononucleo-
some occurs as a result of SGR-induced disruption of histone-
DNA interaction. The dual-binding ability of SGR with DNA and
core histones could be a potential cause of the disruption.
Analysis of CD spectra in the region of 310–380 nm suggests
that the chiro-optical environments of the chromophore are
different in chromatin, mononucleosome, and chromosomal
DNA (Figure 2A). Differential position of the bielliptical positive
induced band of polymer-bound SGR could be ascribed to local
perturbation of binding mode by histones. This in turn gives rise
to difference in binding site microenvironment and geometry
after binding to chromatin and mononucleosome. Increase of
positive CD signal at 272 nm could be ascribed to intercalation
within DNA of native chromatin (Vergani et al., 1994). A control
experiment with ethidium bromide (EtBr) showed an enhance-
ment of molar ellipticity value from 3161 to 5283 (data not
shown). Thus, binding of SGR can be expected to enhance the
CD signal at 272 nm. In contrast, molar ellipticity value for chro-
matin at 272 nm decreases from 3161 to 2461 in the presence of
SGR. The molar ellipticity value at 272 nm for chromatin shows
a decrease with slow kinetics in the presence of SGR (inset of
Figure 2A). Such a decrease in the CD band at 272 nm for chro-
matin is consistent with the proposition of SGR-induced chro-
matin aggregation (Das et al., 2006).
The effect of SGR upon size distribution of the chromatin,
mononucleosome, and chromosomal DNA (Figure 2C) demon-
strates that the alkaloid specifically aggregates chromatin.
Confocal and atomic forcemicroscopy results (Figure 2D, panels
I and II; Figure 2E, panel I, compare i and ii with iii) show that
chromatin aggregation leads to its compaction in the HeLa cells.
AFM studies of isolated nuclei from HeLa cells subjected to
partial MNase digestion indicate that SGR treatment leads to212 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elsthe formation of large compact chromatin domains that could
be an indicative of transcriptional silencing (Figure 2E, panel II,
compare iv and v with vi).
Sanguinarine is a potent inhibitor of histone-modifying
enzymes in vitro. This can be explained by the general blocking
of histones, thereby being inaccessible to the enzymes. The inhi-
bition of histone methyltransferase activity by SGR is interesting.
Although H3K9 methylation by G9a could be inhibited by SGR
in vitro, this highly stable modification in the heterochromatin
domain (Tachibana et al., 2001) was minimally affected by the
presence of 2 mM SGR in vivo. This is expected because the
modification within the cellular system (unlike the in vitro assays)
does not occur as an exclusive event, but rather is modulated by
other epigenetic marks and interacting proteins. Arginine meth-
ylation of H3R17, which along with histone acetylation sets the
chromatin in an active state (Stallcup et al., 2000), was signifi-
cantly reduced upon SGR treatment. Lysine methylation of
H3K4, which is also associated with the transcriptionally active
chromatin, was strongly inhibited by SGR. These observations
suggest that SGR could inhibit the histone modifications
in vitro by a general mechanism of binding to histones and
making it unavailable for enzymatic activity. The kinetic analysis
of SGR-mediated inhibition of the arginine methyltransferase
CARM1 exhibits an uncompetitive mode of inhibition (Figure S4),
indicating the involvement of the enzyme substrate complex in
the inhibition. However, in the cells, SGR could alter the histone
modifications that are transiently induced for activation associ-
ated gene expression more profoundly than those that are the
more stable silent marks like H3K9 methylation, indicating a
preference toward the transcriptionally active foci.
Sanguinarine could inhibit the HAT activity of p300 and PCAF
potently, in vitro and in vivo. A previous report suggested that
SGR is a potent inhibitor of the NF-kB pathway (Chaturvedi
et al., 1997). Acetylation of one of the NF-kB subunits, p65, is
essential for NF-kB activation (Chaturvedi et al., 1997). SGR
might inhibit the acetylation of p65, thereby causing the inhibition
of NF-kB activity. It is yet to be investigatedwhether SGRdirectly
interacts with p300 and inhibits the acetyltransferase activity
irrespective of the substrates (histones or nonhistones). The
SGR inhibition kinetics with p300 exhibit a mixed type of inhibi-
tion with both the substrates (Figure S5). The result is preliminary
evidence of the ability of SGR to bind to the enzyme, but the
affinity of SGR is highly increased in the presence of the
enzyme-substrate complex leading to a mixed inhibition. Thus,
the kinetic analysis with both enzymes (CARM1 and p300) shows
a clear indication toward the involvement of the substrate in the
inhibition. Although SGR inhibited the activity of histone acetyl-
transferase, it does not inhibit histone deacetylase (HDAC1)
activity (Figure S6). Interestingly, in both the enzymatic reactions,
core histones are the common substrates, but the acetylated
form is required for the deacetylation reaction. This indicates
that SGR might not prefer to bind to the acetylated histones,
and thus could not inhibit the HDAC1 activity. SGR is a potent
DNA intercalator. Surprisingly, it could not affect the in vitro tran-
scription from the DNA template even at 75 mM concentration.
However, histone-acetylation-dependent chromatin transcrip-
tion was strongly inhibited in a dose-dependent manner. These
data suggest that through its histone interaction (and thereby
HAT inhibitory ability), SGR might alter the global geneevier Ltd All rights reserved
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aggregation might also contribute to this process by reorganiz-
ing the chromatin territories (Fraser and Bickmore, 2007), which
might also affect the gene expression globally.
Treatment of HeLa cells with 2 mM SGR for 3 hr (a dosage at
which apoptosis is not induced) resulted in almost an equal upre-
gulation and downregulation of genes. Inhibition of histone acet-
ylation andH3R17 andH3K4methylation bySGRcould be attrib-
uted to the downregulation of gene expression. However,
upregulation of gene expression might be caused by the alter-
ation of chromatin organization (aggregation), and inhibition of
a specific set of chromatin-modifying enzyme activity. Further-
more, under specific consequences, p300 might also induce
transcriptional repression (Mantelingu et al., 2007, Sankar et al.,
2008). The functional genes are present in a three-dimensional
microenvironment (chromatin territories), and any alteration of
this structural organization might lead to the exposure of the
buried regions to the transcriptionally active foci, resulting in
gene expression. Many candidate genes of the cell communica-
tion pathway like collagen, keratin, and vitronectin were upregu-
lated. These genes have a role in ECM receptor interaction and in
focal adhesion. This indicates that the early event in SGR treat-
ment might be targeted toward the extracellular regions.
However, kinases like PRKCE andSOCS, which are suppressors
of cytokine signaling, were also upregulated, indicating the phys-
iological activation of signaling process.By contrast, the downre-
gulated genes were mostly members of metabolic pathways,
which is an implication on the early effect of SGR on important
metabolic processes because of its modulation of chromatin
modifications and not due to any interaction with cellular compo-
nents. This phenomenon was verified by an in vitro assay with an
importantmetabolic, nonchromatin enzymeGAPDH (glyceralde-
hyde-3-phosphate dehydrogenase). SGR did not affect the
dehydrogenase activity of GAPDH even at 50 mM concentration
as observed from the absorbance values (Figure S7, lanes 3–7).
However, garcinol, a potent apoptosis-inducing agent that is
known to affect important metabolic pathways (Balasubrama-
nyam et al., 2004a), could inhibit the dehydrogenase activity of
GAPDH completely at 50 mM concentration (Figure S7, lane 8).
Microarray analysis of 5 mM SGR-treated HeLa cells resulted
in a large upregulation of genes (225), whereas 36 genes were
found to be downregulated. The upregulation of several genes
upon SGR treatment was not quite surprising, as previous
reports suggest that SGR induces DNA damage as well as
apoptosis. Apart from these evidences, this could also be an
effect of the physical alteration of chromatin structure by SGR
(as discussed above). The downregulation of HMGA2 is an indi-
cation of the loss of the structural proteins of chromatin.
However, downregulation of genes in presence of SGR could
be due to the inhibition of chromatin modifications (especially
acetylation). Among the upregulated genes, many play a role in
DNA repair. Therefore, these results confirm that SGR indeed
targets DNA and causes its damage. Many genes involved in
cell growth, differentiation, and morphogenesis were upregu-
lated. SGR was known to cause cell death in numerous cancer
cell lines through the accumulation of CyclinD1 and topoisomer-
ase II in cytoplasm (Holy et al., 2006). Our results indeed show
the upregulation of topoisomerase II as one of the candidate
genes. Among the downregulated genes, many are involved inChemistry & Biology 16, 203cell growth, gene regulation, and various cancers. Rab3 (a
member of RAS oncogene family) levels, which are elevated in
various cancers, was downregulated upon SGR treatment.
Modulation of arachidonic acid metabolism is a novel target for
cancer therapy. Cytochrome P450, which plays a crucial role in
the arachidonic acid pathway, was downregulated in our micro-
array analysis. Representative genes that were validated were
specifically modulated by p300 in our previouswork on a specific
inhibitor of p300 (Mantelingu et al., 2007). The upregulation of
PLIN and DIABLO, and the downregulation of ATF6 and
HMGA2, are similar to p300-specific inhibition. These data
clearly indicate the dual mechanism of an SGR-mediated anti-
cancer effect wherein the epigenetic mode of repression is func-
tional at an early preapoptotic stage along with the later event of
apoptosis induction. This mode of action might be similar for all
DNA-binding drugs that also interact with chromatin.
In order to understand the mechanism of action of this impor-
tant plant alkaloid as a putative anticancer compound, it would
be essential to consider the interactions of SGRwith the dynamic
chromatin components and the subsequent alterations of post-
translational modifications of histones and nonhistone proteins.
However, derivatization of SGR and related alkaloids could be
useful to design more specific and relatively less cytotoxic anti-
neoplastic therapeutics, which could act on chromatin modifica-
tions in a more targeted manner.
SIGNIFICANCE
In this report, we show that SGR, a putative anticancer DNA
intercalator, interacts not only with DNA but also with
histones. SGR inhibits important chromatin modifications
like acetylation and methylation. Remarkably, SGR could
inhibit the transcription from chromatin template but not
DNA. In vivo, SGR modulates the expression of a large
number of genes differentially based on dosage. It exhibits
a dual mechanism of action, wherein the initial effects are
due to the alteration of the epigenetic marks. The secondary
effects are due to SGR-mediated activation of the apoptotic
pathway. These results establish a unique perspective of
DNA-binding drugs and demand a new set of investigations
about these compounds regarding their effect on epigenetic
alterations. These data would be highly useful in under-
standing the mechanism of action of anticancer drugs as
well as in designing new-generation therapeutics.
EXPERIMENTAL PROCEDURES
Preparation of Chromatin and Mononucleosome from Rat Liver
Male albino Sprague-Dawley rats weighing about 150 ± 10 g and about 2 or 3
months old were used throughout this study. Nuclei were isolated from the
homogenized liver by using a standard method described elsewhere (Blobel
and Potter, 1966; Burton., 1956).
Preparation of Chromatin from HeLa Cells
Chromatin from HeLa cells was isolated by using a standard method
described elsewhere (Das et al., 2006).
Absorbance and Fluorescence Measurement
Absorption spectra were recorded with a CECIL 7500 spectrophotometer. The
concentration of SGR in 10 mM Na-acetate (pH 5.2) was estimated with the
molar absorption coefficient (3) of 30,700 M1cm1 at 327 nm. Fluorescence–216, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 213
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trometer using 1 cm path length quartz cuvettes. Excitation and emission slits
with a band pass of 5 nm and 10 nm, respectively, were used for all measure-
ments. During fluorescence measurements, absorbance of the samples did
not exceed 0.05 at 327 nm. Therefore, we did not correct the emission intensity
for optical filtering effect. The excitation and emission wavelengths were 327
and 570 nm, respectively.
Fluorescence Lifetime Measurements
Fluorescence lifetimes were calculated from time-resolved fluorescence
decays using a luminescence spectrophotometer (Edinburgh Instruments
Ltd., Scotland) in the time-correlated single photon counting mode. The exci-
tation source is a nanosecond flash lamp filled with nitrogen as plasma gas.
Lamp profiles were measured at the excitation wavelength (327 nm) using
Ludox (colloidal silica) as the scatterer. For each measurement, 3000 photon
counts were collected in the peak channel. All experiments were performed
using excitation and emission slits with a nominal band pass of 4 nm. Intensity
decay curves were fitted as a sum of exponential terms:
FðtÞ=
X
i
ai expð  t=tiÞ
where ai is a pre-exponential factor representing the fractional contribution to
the time-resolved decay of the component with a lifetime ti. The decay param-
eters were recovered using a nonlinear least-squares iterative fitting proce-
dures based on the Marquardt algorithm (Bevington, 1969). The goodness of
fit of a given set of observed data and the chosen function was evaluated by
the reduced c2 value not more than 1.5. Mean (average) lifetime < t > for biex-
ponential decays of fluorescence was calculated from the decay times and
pre-exponential factors using the following equation (Lakowich, 1999):
<t>=
a1t12 +a2t22
a1t1+a2t2
Circular Dichroic Spectroscopy
Circular dichroism measurements were done in a JASCO J-720 spectropo-
larimeter (Jasco Corporation, Tokyo, Japan) at 25C equipped with a temper-
ature controller. The CD scans were recorded within the wavelength range of
200–400 nm at sensitivity set to 10 mdeg and scan speed 20 nm per minute
with step size of 0.5 nm. The time constant was 1 s and bandwidth was
0.2 nm. All measurements were done in a cuvette of 1 cm path length in a reac-
tion volume of 2 ml in 10 mM Tris-HCl (pH 6.5) at 25C. In a reaction mixture
containing 10 mM SGR, individual titration was performed with different levels
of chromatin structure (polymers) to achieve a concentration range of 2.8 to
39 mM. The reaction mixture was incubated for 2 min before scanning. All
spectra are average of three runs. They were smoothed within the permissible
limits by the inbuilt software of the instrument.
Isothermal Titration Calorimetry
Isothermal calorimetric measurements were performed in a VP-ITC microcal-
orimeter (Microcal Inc.) at different temperatures between 10C to 30C.
Samples were centrifuged and degassed before titration. Titration of SGR
against different levels of chromatin structure was performed by injecting poly-
mers into SGR. A blank experiment in which polymers were injected into buffer
with no SGR was done to correct the data due to dilution. Background was
subtracted from the measured heats, and the corrected heats were plotted
against molar ratio and analyzed using manufacturer’s software yielding the
stoichiometry n (in terms of number of bases/drug molecule), equilibrium
dissociation constant (Kd = 1/Ka), and enthalpy (DH). From the relationship
DG =RT ln Ka and the Gibbs-Helmholtz equation, the entropy of association
(DS) was calculated. Change in heat capacity (DCp) for the association of SGR
with different polymers was calculated from the plot of enthalpy change (DH)
against temperature.
Dynamic Light Scattering
Dynamic light scattering experiments were performed using the Zetasizer
Nanoseries (Malvern Instruments) equipped with a 4 mW He-Ne laser (l =
632 nm). This instrument measures the fluctuation in scattering intensity and
uses this to determine the diffusion coefficient, Q, of the sample by means214 Chemistry & Biology 16, 203–216, February 27, 2009 ª2009 Elseof its inbuilt autocorrelator. Size of the particles is calculated using Stokes-
Einstein equation:
DH =
kT
f
=
kT
3phQ
where DH is the hydrodynamic diameter, k is the Boltzmann constant, f is
particle frictional coefficient, h is solvent viscosity (here, we have given the
viscosity of water as the solvent viscosity), T is the absolute temperature,
and Q is the diffusion coefficient.
Binding Analysis
Results from fluorimetric titrations were analyzed with a standard method
described elsewhere (Mir and Dasgupta, 2001). Binding stoichiometry
(expressed in terms of site size) was estimated from the intersection of the
two straight lines of a least-squares fit plot of normalized change in fluores-
cence against the input concentration of the polymer.
Confocal Microscopy
HeLa cells were cultured as monolayer on the poly-L-lysine-coated coverslips
in Dulbecco’s minimal essential medium (Sigma). SGR-treated (2 mM) cells
were then fixed. Nuclear staining of fixed cells was done with Hoechst
33258 (Sigma). Images were taken with a Zeiss LSM 510 META confocal
microscope.
Atomic Force Microscopy
Nuclei were isolated from SGR-treated (2 mM) HeLa cells as described else-
where. After subjecting the nucleus to MNase digestion, samples were fixed
and dried for AFM visualization. AFM observation was performed with a Bio-
scope/Bioscope SZ; Nanoscope IIIa controller (Veeco Instruments Inc., Santa
Barbara, CA, USA) using the contact mode. The cantilever (nonconductive
silicon nitride, Veeco model DNP-20) was in 0.4–0.7 mm long with a spring
constant of 0.06 N/m. The scanning frequency was 1.001 Hz, and images
are captured with the height mode in a 2563 256 and 5123 512 pixel format.
Purification of Human Core Histones and Recombinant Proteins
Human core histones were purified from HeLa nuclear pellet as described
previously (Kundu et al., 1999). Purification of recombinant p300, G9a,
CARM-1, PCAF, HDAC1, NAP1, and Gal4-VP16 was performed as described
elsewhere (Kundu et al., 2000, Balasubramanyam et al., 2004a, 2004b).
Histone Acetyltransferase and Deacetylase Assay
The HAT and HDAC assays were performed as described previously (Kundu
et al., 2000, Balasubramanyam et al., 2004a, 2004b).
Analysis of In Vivo Histone Acetylation
The histone modification analysis in the HeLa cells on SGR treatment was
done as described previously (Mantelingu et al., 2007). For the animal exper-
iment, SGR 25 mg/kg body weight in 50 ml DMSO was injected to mice, which
were killed after 6 hr. Mice liver tissue was processed for paraffin embedding
followed by microtome sectioning and processing for immunohistochemical
staining with acetylated histone H3 antibody.
Histone Methyltransferase Assays
Histone methyltransferase assays were performed in a 30 ml reaction. The
reaction mixture containing highly purified HeLa core histones, with or without
histone methyltransferases in the HMT assay buffer 20 mM Tris, 4 mM EDTA
(pH 8.0), 200 mM NaCl, along with varying concentrations of SGR for 10 min
at 30C. After the initial incubation, 1 ml 15 Ci/mmol [3H] (S)-adenosyl methio-
nine (Amersham) was added to the reaction mixtures, and the incubation
continued for 15 min. The reaction mixture was then blotted onto P-81 (What-
man) filter paper, and radioactive counts were recorded on a PerkinElmer Wal-
lac 1409 liquid scintillation counter. The reaction products were TCA precipi-
tated, resolved on 15% SDS-PAGE, and subjected to fluorography followed
by autoradiography.
Analysis of In Vivo Histone Methylation
The histone modification analysis in the HeLa cells on SGR treatment was
done as described previously (Mantelingu et al., 2007), using the followingvier Ltd All rights reserved
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(Upstate), and trimethylated H3K4 (Upstate).
In Vitro Transcription
DNA and chromatin transcription assays were performed as described earlier
with minor modifications (Kundu et al., 2000, Balasubramanyam et al., 2004a,
2004b).
Microarray Analysis
HeLa cells were treated with the indicated concentration of SGR (2 mM or
5 mM). The DMSO-treated cells were used as control. RNA was isolated after
the indicated time of treatment (3 hr or 12 hr, respectively). The 2 mM treated
samples were hybridized on Agilent human 15K whole genome array. The
5 mM treated samples were hybridized on Toronto human 19K whole genome
array. Data analysis was done using GeneSpring software. The normalization
was done using GeneSpring GX using the recommended per spot, per chip
intensity dependent (lowest) normalization.
Endogenous Gene Expression Assay by Real-Time Polymerase
Chain Reaction Analysis
HeLa cells were treatedwith SGR for the indicated time point with the indicated
concentration. DMSO-treated cells were used as controls. Following the stip-
ulated time of treatment, the total RNA was isolated using Trizol reagent (Invi-
trogen). The cDNA was amplified with oligo dT (28-mer) (Invitrogen) by MMLV
reverse transcriptase (Sigma), and the expression analysis was done with the
help of iQTM SyBR green supermix (Bio-Rad) and gene-specific primers of
actin and CHFR3 (forward primer: 50- TGGGTTTCCTGTGCTAATG-30, reverse
primer: 50-AGTCTCAAAATGTTCATCAC-30), PRKCH (forward primer: 50-GA
AAAGTCCCACGGAGGAG-30, reverse primer: 50-TGCTTCGCAGCGGGA
GAACCG-30), MEF2C (forward primer: 50-CTGCATGTTTGAATCAGGTG-30,
reverseprimer: 50-ATTCGTTCCTGATGAAGGAAG-30),DPPA2 (forwardprimer:
50-ATCAACTTGATGAAGGAAG-30, reverse primer: 50-ATCCAAATTTGCATC
TGAC-30), DIABLO (forward primer: 50-CAGAGGAGGAAGATGAAGTG-30,
reverse primer: 50-CAATCCTCACGCAGGTAGGC-30), PLIN (forward primer:
50-CAGGAGAATGTGCTGCAGCG-30, reverse primer, 50-AGGCGGGTGGAG
ATGGTGTC-30), ATF6 (forward primer: 50-GACTCTTTCACAGGCTGGA-30,
reverse primer: 50-CTTCCTTCAGTGGCTCCGC-30), HMGA2 (forward primer,
50-ATGAGCGCACGCGGTGAG-30, reverse primer: 50-GTGATCCTCTTCGG
CAGAC-30).
For technical details regarding the DLS studies, HDAC assay, in vitro tran-
scription, purification of human core histones, and other recombinant proteins,
please refer to Supplemental Experimental Procedures.
ACCESSION NUMBER
Guidelines set by MIAME were followed, and the raw microarray data have
been deposited in NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE14314) and are accessible through
GEO Series accession number GSE14314 and GSE14777.
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